RankAlpha logo
Back to Rankings

PALI

Palisade BioB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
September FDA clearance for ASCENTRA-CD and Health Canada clearance for ASCENTRA-UC remove two regulatory-start hurdles. The company reported $125.2 million of cash at June 30 and expects resources to fund both planned Phase 2 readouts.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
ASCENTRA-CD’s single-arm design may complicate interpretation of efficacy relative to a controlled study. [#PR-2026-09-22]
Momentum
85
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.35 · Bull $2.35 · Bear $0.65Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-28 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-28

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum85 · Δ7d -
Value41 · Δ7d -0.1
Sentiment77 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • ASCENTRA-CD’s single-arm design may complicate interpretation of efficacy relative to a controlled study. [#PR-2026-09-22]
  • • Phase 1 signals from very small patient cohorts may not replicate in controlled Phase 2 testing. [#SEC-8K-2026-08-10]
  • • PALI-2108 remains clinically unproven in Phase 2.

Catalyst clock

2026-10-20

UEG Week PALI-2108 presentations

Lead driver: Sentiment · See AI snapshot
Momentum
85
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
77
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 84.6 / Value 40.6 / Sentiment 77.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method

B+
Bull case
25%
Probability
Target price
$2.35
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Most likely
B
Base case
40%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-28
Market Cap
$207.38M
Beta
1.61
Shares Out
174.27M
P/E (TTM) · Derived
-3.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.17
Rev YoY
-100.0%
EPS YoY
-91.4%
Gross Margin
+78.4%
Op Margin
-
Net Debt
-$133.31M
Current Ratio
24.25
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data